Association of activated c-Met with NRAS-mutated human melanomas: A possible avenue for targeting

International Journal of Cancer

Volumn 131, Issue 2, 2012, Pages

  Chattopadhyay, Chandrani ^a   Ellerhorst, Julie A ^a   Ekmekcioglu, Suhendan ^a   Greene, Victoria R ^a   Davies, Michael A ^a   Grimm, Elizabeth A ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

c Met; HGF; melanoma; NRAS mutation; PHA665752

Indexed keywords

5 (2,6 DICHLOROBENZYLSULFONYL) 3 [3,5 DIMETHYL 4 [2 (1 PYRROLIDINYLMETHYL) 1 PYRROLIDINYLCARBONYL] 1H PYRROL 2 YLMETHYLENE] 1,3 DIHYDRO 2H INDOL 2 ONE; B RAF KINASE; SCATTER FACTOR RECEPTOR;

ADULT; ARTICLE; CANCER LOCALIZATION; CONTROLLED STUDY; FEMALE; GENE MUTATION; GENE SILENCING; GENE TARGETING; GENETIC ASSOCIATION; GENOTYPE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOPRECIPITATION; MALE; MELANOMA; ONCOGENE N RAS; PRIORITY JOURNAL; PROTEIN DETERMINATION; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; SKIN CARCINOGENESIS; WESTERN BLOTTING;

APOPTOSIS; CELL LINE, TUMOR; CELL MOVEMENT; CELL PROLIFERATION; FEMALE; GENES, RAS; HEPATOCYTE GROWTH FACTOR; HUMANS; INDOLES; MALE; MELANOMA; MIDDLE AGED; MUTATION; PHOSPHORYLATION; PROTO-ONCOGENE PROTEINS B-RAF; PROTO-ONCOGENE PROTEINS C-AKT; PROTO-ONCOGENE PROTEINS C-MET; PROTO-ONCOGENE PROTEINS P21(RAS); RNA INTERFERENCE; RNA, SMALL INTERFERING; SIGNAL TRANSDUCTION; SULFONES;

EID: 84861583077     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.26487     Document Type: Article

References (35)

1. To CT, Tsao MS,. The roles of hepatocyte growth factor/scatter factor and met receptor in human cancers (Review). Oncol Rep 1998; 5: 1013-24.
2. Gherardi E, Sharpe M, Lane K, Sirulnik A, Stoker M,. Hepatocyte growth factor/scatter factor (HGF/SF), the c-met receptor and the behaviour of epithelial cells. Symp Soc Exp Biol 1993; 47: 163-81.
3. Park M, Dean M, Cooper CS, Schmidt M, O'Brien SJ, Blair DG, Vande Woude GF,. Mechanism of met oncogene activation. Cell 1986; 45: 895-904.
4. Ma PC, Jagadeeswaran R, Jagadeesh S, Tretiakova MS, Nallasura V, Fox EA, Hansen M, Schaefer E, Naoki K, Lader A, Richards W, Sugarbaker D, et al. Functional expression and mutations of c-Met and its therapeutic inhibition with SU11274 and small interfering RNA in non-small cell lung cancer. Cancer Res 2005; 65: 1479-88.
5. Peruzzi B, Bottaro DP,. Targeting the c-Met signaling pathway in cancer. Clin Cancer Res 2006; 12: 3657-60.
6. Furge KA, Zhang YW, Vande Woude GF,. Met receptor tyrosine kinase: enhanced signaling through adapter proteins. Oncogene 2000; 19: 5582-89.
7. Ma PC, Tretiakova MS, Nallasura V, Jagadeeswaran R, Husain AN, Salgia R,. Downstream signalling and specific inhibition of c-MET/HGF pathway in small cell lung cancer: implications for tumour invasion. Br J Cancer 2007; 97: 368-77.
8. Puri N, Ahmed S, Janamanchi V, Tretiakova M, Zumba O, Krausz T, Jagadeeswaran R, Salgia R,. c-Met is a potentially new therapeutic target for treatment of human melanoma. Clin Cancer Res 2007; 13: 2246-53.
9. Halaban R, Rubin JS, Funasaka Y, Cobb M, Boulton T, Faletto D, Rosen E, Chan A, Yoko K, White W, et al. Met and hepatocyte growth factor/scatter factor signal transduction in normal melanocytes and melanoma cells. Oncogene 1992; 7: 2195-206.
10. Cruz J, Reis-Filho JS, Silva P, Lopes JM,. Expression of c-met tyrosine kinase receptor is biologically and prognostically relevant for primary cutaneous malignant melanomas. Oncology 2003; 65: 72-82.
11. Saitoh K, Takahashi H, Sawada N, Parsons PG,. Detection of the c-met proto-oncogene product in normal skin and tumours of melanocytic origin. J Pathol 1994; 174: 191-9.
12. Riker AI, Enkemann SA, Fodstad O, Liu S, Ren S, Morris C, Xi Y, Howell P, Metge B, Samant RS, Shevde LA, Li W, et al. The gene expression profiles of primary and metastatic melanoma yields a transition point of tumor progression and metastasis. BMC Med Genomics 2008; 1: 13.
13. Otsuka T, Takayama H, Sharp R, Celli G, LaRochelle WJ, Bottaro DP, Ellmore N, Vieira W, Owens JW, Anver M, Merlino G,. c-Met autocrine activation induces development of malignant melanoma and acquisition of the metastatic phenotype. Cancer Res 1998; 58: 5157-67.
14. Goydos JS, Mann B, Kim HJ, Gabriel EM, Alsina J, Germino FJ, Shih W, Gorski DH,. Detection of B-RAF and N-RAS mutations in human melanoma. J Am Coll Surg 2005; 200: 362-70.
15. Weber J,. Immunotherapy for melanoma. Curr Opin Oncol 2011; 23: 163-9.
16. Chapman PB, Hauschild A, Robert C, Haanen JB, Ascierto P, Larkin J, Drummer R, Garbe C, Testori A, Maio M, Hogg D, Lorogan P, et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med 2011; 364: 2507-16.
17. Davies MA, Samuels Y,. Analysis of the genome to personalize therapy for melanoma. Oncogene 2010; 29: 5545-55.
18. Ball NJ, Yohn JJ, Morelli JG, Norris DA, Golitz LE, Hoeffler JP,. RAS mutations in human melanoma: a marker of malignant progression. J Invest Dermatol 1994; 102: 285-90.
19. Uffort DG, Grimm EA, Ellerhorst JA,. NF-kappaB mediates mitogen-activated protein kinase pathway-dependent iNOS expression in human melanoma. J Invest Dermatol 2009; 129: 148-54.
20. Romano P, Manniello A, Aresu O, Armento M, Cesaro M, Parodi B,. Cell line data base: structure and recent improvements towards molecular authentication of human cell lines. Nucleic Acids Res 2009; 37: D925-32.
21. Ellerhorst JA, Greene VR, Ekmekcioglu S, Warneke CL, Johnson MM, Cooke CP, Wang LE, Prieto VG, Gershenwald JE, Wei Q, Grimm EA,. Clinical correlates of NRAS and BRAF mutations in primary human melanoma. Clin Cancer Res 2011; 17: 229-35.
22. Ellerhorst JA, Prieto VG, Ekmekcioglu S, Broemeling L, Yekell S, Chada S, Grimm EA,. Loss of MDA-7 expression with progression of melanoma. J Clin Oncol 2002; 20: 1069-74.
23. Chattopadhyay C, el-Naggar AK, Williams MD, Clayman GL,. Small molecule c-MET inhibitor PHA665752: effect on cell growth and motility in papillary thyroid carcinoma. Head Neck 2008; 30: 991-1000.
24. Matsubara D, Ishikawa S, Oguni S, Aburatani H, Fukayama M, Niki T,. Molecular predictors of sensitivity to the MET inhibitor PHA665752 in lung carcinoma cells. J Thorac Oncol 2010; 5: 1317-24.
25. Burgess T, Coxon A, Meyer S, Sun J, Rex K, Tsuruda T, Chen Q, Ho SY, Li L, Kaufman S, McDorman K, Cattley RC, et al. Fully human monoclonal antibodies to hepatocyte growth factor with therapeutic potential against hepatocyte growth factor/c-Met-dependent human tumors. Cancer Res 2006; 66: 1721-29.
26. Jin H, Yang R, Zheng Z, Romero M, Ross J, Bou-Reslan H, Carano RA, Kasman I, Mai E, Young J, Zha J, Zhang Z, et al. MetMAb, the one-armed 5D5 anti-c-Met antibody, inhibits orthotopic pancreatic tumor growth and improves survival. Cancer Res 2008; 68: 4360-8.
27. Firon M, Shaharabany M, Altstock RT, Horev J, Abramovici A, Resau JH, Vande Woude GF, Tsarfaty I,. Dominant negative Met reduces tumorigenicity- metastasis and increases tubule formation in mammary cells. Oncogene 2000; 19: 2386-97.
28. Shinomiya N, Gao CF, Xie Q, Gustafson M, Waters DJ, Zhang YW, Vande Woude GF,. RNA interference reveals that ligand-independent met activity is required for tumor cell signaling and survival. Cancer Res 2004; 64: 7962-70.
29. Christensen JG, Zou HY, Arango ME, Li Q, Lee JH, McDonnell SR, Yamazaki S, Alton GR, Mroczkowski B, Los G,. Cytoreductive antitumor activity of PF-2341066, a novel inhibitor of anaplastic lymphoma kinase and c-Met, in experimental models of anaplastic large-cell lymphoma. Mol Cancer Ther 2007; 6: 3314-22.
30. Zou HY, Li Q, Lee JH, Arango ME, McDonnell SR, Yamazaki S, Koudriakova TB, Alton G, Cui JJ, Kung PP, Nambu MD, Los G, et al. An orally available small-molecule inhibitor of c-Met, PF-2341066, exhibits cytoreductive antitumor efficacy through antiproliferative and antiangiogenic mechanisms. Cancer Res 2007; 67: 4408-17.
31. Buchanan SG, Hendle J, Lee PS, Smith CR, Bounaud PY, Jessen KA, Tang CM, Huser NH, Felce JD, Froning KJ, Peterman MC, Aubol BE, et al. SGX523 is an exquisitely selective, ATP-competitive inhibitor of the MET receptor tyrosine kinase with antitumor activity in vivo. Mol Cancer Ther 2009; 8: 3181-90.
32. Jeay S, Munshi N, Hill J, Moussa M, Ashwell M, Leggett D, Li C,. ARQ197, a highly selective small molecule inhibitor of c-Met, with selective antitumor properties in a broad spectrum of human cancer cells. 2007 AACR Annual Meeting 2007 (abstract).
33. Polakis P, McCormick F,. Structural requirements for the interaction of p21ras with GAP, exchange factors, and its biological effector target. J Biol Chem 1993; 268; 9157-60.
34. Webb CP, Taylor GA, Jeffers M, Fiscella M, Oskarsson M, Resau JH, Vande Woude GF,. Evidence for a role of Met-HGF/SF during Ras-mediated tumorigenesis/metastasis. Oncogene 1998; 17: 2019-25.
35. Ueoka Y, Kato K, Wake N,. Hepatocyte growth factor modulates motility and invasiveness of ovarian carcinomas via ras mediated pathway. Mol Cell Endocrinol 2003; 202: 81-8.